(BDX) Becton Dickinson - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0758871091
Catheters, Syringes, Infusion, Diagnostics, Surgical
Total Rating 34
Risk 79
Buy Signal -0.90
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.15% |
| Yield on Cost 5y | 1.77% |
| Yield CAGR 5y | 5.55% |
| Payout Consistency | 80.8% |
| Payout Ratio | 28.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.6% |
| Relative Tail Risk | -7.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.59 |
| Alpha | -28.59 |
| Character TTM | |
|---|---|
| Beta | 0.560 |
| Beta Downside | 0.694 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.06% |
| CAGR/Max DD | -0.14 |
Description: BDX Becton Dickinson January 29, 2026
Becton, Dickinson & Company (BDX) is a diversified medical-technology firm that designs, manufactures and markets a broad portfolio of products-including IV catheters, drug-delivery and safety systems, laboratory automation, diagnostic reagents, and surgical supplies-served through five operating segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. Its customers span hospitals, clinics, research labs, pharmaceutical manufacturers and the broader public health ecosystem.
Key recent metrics (FY 2025): revenue $25.1 billion (+5.2% YoY), adjusted EPS $9.84 (+7.1% YoY), and a free-cash-flow conversion of 68%. The Connected Care segment grew 9% on a 3-year compound annual growth rate (CAGR) of 5.8%, driven by rising demand for medication-automation and analytics solutions in outpatient settings. A primary sector driver is the aging U.S. population, which is projected to increase hospital admissions for chronic-care procedures by ~1.4% annually through 2030, bolstering demand for BD’s vascular access and infection-prevention products.
For a deeper quantitative assessment, you may find ValueRay’s platform useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 1.60b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.61 > 1.0 |
| NWC/Revenue: 4.24% < 20% (prev 7.49%; Δ -3.25% < -1%) |
| CFO/TA 0.10 > 3% & CFO 5.64b > Net Income 1.60b |
| Net Debt (18.54b) to EBITDA (3.48b): 5.32 < 3 |
| Current Ratio: 1.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (285.4m) vs 12m ago -1.79% < -2% |
| Gross Margin: 45.40% > 18% (prev 0.45%; Δ 4495 % > 0.5%) |
| Asset Turnover: 39.47% > 50% (prev 35.22%; Δ 4.24% > 0%) |
| Interest Coverage Ratio: 2.66 > 6 (EBITDA TTM 3.48b / Interest Expense TTM 616.0m) |
Altman Z'' 1.88
| A: 0.02 (Total Current Assets 9.26b - Total Current Liabilities 8.31b) / Total Assets 55.33b |
| B: 0.30 (Retained Earnings 16.62b / Total Assets 55.33b) |
| C: 0.03 (EBIT TTM 1.64b / Avg Total Assets 56.31b) |
| D: 0.57 (Book Value of Equity 16.99b / Total Liabilities 29.93b) |
| Altman-Z'' Score: 1.88 = BBB |
Beneish M -3.11
| DSRI: 0.90 (Receivables 2.99b/3.03b, Revenue 22.22b/20.18b) |
| GMI: 1.00 (GM 45.40% / 45.36%) |
| AQI: 1.01 (AQ_t 0.71 / AQ_t-1 0.70) |
| SGI: 1.10 (Revenue 22.22b / 20.18b) |
| TATA: -0.07 (NI 1.60b - CFO 5.64b) / TA 55.33b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of BDX shares?
As of January 29, 2026, the stock is trading at USD 201.92 with a total of 1,440,010 shares traded.
Over the past week, the price has changed by -2.07%, over one month by +3.46%, over three months by +10.21% and over the past year by -17.18%.
Over the past week, the price has changed by -2.07%, over one month by +3.46%, over three months by +10.21% and over the past year by -17.18%.
Is BDX a buy, sell or hold?
Becton Dickinson has received a consensus analysts rating of 3.59.
Therefor, it is recommend to hold BDX.
- StrongBuy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 206.7 | 2.4% |
| Analysts Target Price | 206.7 | 2.4% |
| ValueRay Target Price | 215.1 | 6.5% |
BDX Fundamental Data Overview January 26, 2026
P/E Trailing = 34.7315
P/E Forward = 13.4771
P/S = 2.6371
P/B = 2.2643
P/EG = 1.0369
Revenue TTM = 22.22b USD
EBIT TTM = 1.64b USD
EBITDA TTM = 3.48b USD
Long Term Debt = 17.62b USD (from longTermDebt, last quarter)
Short Term Debt = 855.0m USD (from shortTermDebt, last quarter)
Debt = 19.18b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 18.54b USD (from netDebt column, last quarter)
Enterprise Value = 76.13b USD (57.59b + Debt 19.18b - CCE 641.0m)
Interest Coverage Ratio = 2.66 (Ebit TTM 1.64b / Interest Expense TTM 616.0m)
EV/FCF = 28.97x (Enterprise Value 76.13b / FCF TTM 2.63b)
FCF Yield = 3.45% (FCF TTM 2.63b / Enterprise Value 76.13b)
FCF Margin = 11.83% (FCF TTM 2.63b / Revenue TTM 22.22b)
Net Margin = 7.19% (Net Income TTM 1.60b / Revenue TTM 22.22b)
Gross Margin = 45.40% ((Revenue TTM 22.22b - Cost of Revenue TTM 12.13b) / Revenue TTM)
Gross Margin QoQ = 47.51% (prev 47.50%)
Tobins Q-Ratio = 1.38 (Enterprise Value 76.13b / Total Assets 55.33b)
Interest Expense / Debt = 0.81% (Interest Expense 155.0m / Debt 19.18b)
Taxrate = 3.33% (17.0m / 510.0m)
NOPAT = 1.59b (EBIT 1.64b * (1 - 3.33%))
Current Ratio = 1.11 (Total Current Assets 9.26b / Total Current Liabilities 8.31b)
Debt / Equity = 0.76 (Debt 19.18b / totalStockholderEquity, last quarter 25.39b)
Debt / EBITDA = 5.32 (Net Debt 18.54b / EBITDA 3.48b)
Debt / FCF = 7.05 (Net Debt 18.54b / FCF TTM 2.63b)
Total Stockholder Equity = 25.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.84% (Net Income 1.60b / Total Assets 55.33b)
RoE = 6.31% (Net Income TTM 1.60b / Total Stockholder Equity 25.31b)
RoCE = 3.82% (EBIT 1.64b / Capital Employed (Equity 25.31b + L.T.Debt 17.62b))
RoIC = 3.57% (NOPAT 1.59b / Invested Capital 44.46b)
WACC = 6.18% (E(57.59b)/V(76.78b) * Re(7.98%) + D(19.18b)/V(76.78b) * Rd(0.81%) * (1-Tc(0.03)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.03%
[DCF Debug] Terminal Value 86.30% ; FCFF base≈2.81b ; Y1≈3.14b ; Y5≈4.17b
Fair Price DCF = 328.6 (EV 112.16b - Net Debt 18.54b = Equity 93.62b / Shares 284.9m; r=6.18% [WACC]; 5y FCF grow 13.83% → 2.90% )
EPS Correlation: 56.46 | EPS CAGR: 2.27% | SUE: 0.27 | # QB: 0
Revenue Correlation: 86.55 | Revenue CAGR: 6.10% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.33 | Chg30d=-0.037 | Revisions Net=-1 | Analysts=9
EPS current Year (2026-09-30): EPS=14.94 | Chg30d=+0.005 | Revisions Net=-1 | Growth EPS=+3.8% | Growth Revenue=+3.1%
EPS next Year (2027-09-30): EPS=15.88 | Chg30d=-0.002 | Revisions Net=+0 | Growth EPS=+6.3% | Growth Revenue=+3.5%
P/E Forward = 13.4771
P/S = 2.6371
P/B = 2.2643
P/EG = 1.0369
Revenue TTM = 22.22b USD
EBIT TTM = 1.64b USD
EBITDA TTM = 3.48b USD
Long Term Debt = 17.62b USD (from longTermDebt, last quarter)
Short Term Debt = 855.0m USD (from shortTermDebt, last quarter)
Debt = 19.18b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 18.54b USD (from netDebt column, last quarter)
Enterprise Value = 76.13b USD (57.59b + Debt 19.18b - CCE 641.0m)
Interest Coverage Ratio = 2.66 (Ebit TTM 1.64b / Interest Expense TTM 616.0m)
EV/FCF = 28.97x (Enterprise Value 76.13b / FCF TTM 2.63b)
FCF Yield = 3.45% (FCF TTM 2.63b / Enterprise Value 76.13b)
FCF Margin = 11.83% (FCF TTM 2.63b / Revenue TTM 22.22b)
Net Margin = 7.19% (Net Income TTM 1.60b / Revenue TTM 22.22b)
Gross Margin = 45.40% ((Revenue TTM 22.22b - Cost of Revenue TTM 12.13b) / Revenue TTM)
Gross Margin QoQ = 47.51% (prev 47.50%)
Tobins Q-Ratio = 1.38 (Enterprise Value 76.13b / Total Assets 55.33b)
Interest Expense / Debt = 0.81% (Interest Expense 155.0m / Debt 19.18b)
Taxrate = 3.33% (17.0m / 510.0m)
NOPAT = 1.59b (EBIT 1.64b * (1 - 3.33%))
Current Ratio = 1.11 (Total Current Assets 9.26b / Total Current Liabilities 8.31b)
Debt / Equity = 0.76 (Debt 19.18b / totalStockholderEquity, last quarter 25.39b)
Debt / EBITDA = 5.32 (Net Debt 18.54b / EBITDA 3.48b)
Debt / FCF = 7.05 (Net Debt 18.54b / FCF TTM 2.63b)
Total Stockholder Equity = 25.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.84% (Net Income 1.60b / Total Assets 55.33b)
RoE = 6.31% (Net Income TTM 1.60b / Total Stockholder Equity 25.31b)
RoCE = 3.82% (EBIT 1.64b / Capital Employed (Equity 25.31b + L.T.Debt 17.62b))
RoIC = 3.57% (NOPAT 1.59b / Invested Capital 44.46b)
WACC = 6.18% (E(57.59b)/V(76.78b) * Re(7.98%) + D(19.18b)/V(76.78b) * Rd(0.81%) * (1-Tc(0.03)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.03%
[DCF Debug] Terminal Value 86.30% ; FCFF base≈2.81b ; Y1≈3.14b ; Y5≈4.17b
Fair Price DCF = 328.6 (EV 112.16b - Net Debt 18.54b = Equity 93.62b / Shares 284.9m; r=6.18% [WACC]; 5y FCF grow 13.83% → 2.90% )
EPS Correlation: 56.46 | EPS CAGR: 2.27% | SUE: 0.27 | # QB: 0
Revenue Correlation: 86.55 | Revenue CAGR: 6.10% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.33 | Chg30d=-0.037 | Revisions Net=-1 | Analysts=9
EPS current Year (2026-09-30): EPS=14.94 | Chg30d=+0.005 | Revisions Net=-1 | Growth EPS=+3.8% | Growth Revenue=+3.1%
EPS next Year (2027-09-30): EPS=15.88 | Chg30d=-0.002 | Revisions Net=+0 | Growth EPS=+6.3% | Growth Revenue=+3.5%